EP1144272B1 - Ventil - Google Patents

Ventil Download PDF

Info

Publication number
EP1144272B1
EP1144272B1 EP00915150A EP00915150A EP1144272B1 EP 1144272 B1 EP1144272 B1 EP 1144272B1 EP 00915150 A EP00915150 A EP 00915150A EP 00915150 A EP00915150 A EP 00915150A EP 1144272 B1 EP1144272 B1 EP 1144272B1
Authority
EP
European Patent Office
Prior art keywords
valve
stem
sealing ring
valve according
metering chamber
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
EP00915150A
Other languages
English (en)
French (fr)
Other versions
EP1144272A2 (de
Inventor
Gregor John Mclennan Anderson
Mark Andrew Hailey
David Joseph Russell
James William Godfrey
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of EP1144272A2 publication Critical patent/EP1144272A2/de
Application granted granted Critical
Publication of EP1144272B1 publication Critical patent/EP1144272B1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
    • B65D83/00—Containers or packages with special means for dispensing contents
    • B65D83/14—Containers or packages with special means for dispensing contents for delivery of liquid or semi-liquid contents by internal gaseous pressure, i.e. aerosol containers comprising propellant for a product delivered by a propellant
    • B65D83/44—Valves specially adapted therefor; Regulating devices
    • B65D83/48—Lift valves, e.g. operated by push action
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
    • B65D83/00—Containers or packages with special means for dispensing contents
    • B65D83/14—Containers or packages with special means for dispensing contents for delivery of liquid or semi-liquid contents by internal gaseous pressure, i.e. aerosol containers comprising propellant for a product delivered by a propellant
    • B65D83/44—Valves specially adapted therefor; Regulating devices
    • B65D83/52—Valves specially adapted therefor; Regulating devices for metering
    • B65D83/54—Metering valves ; Metering valve assemblies

Definitions

  • This invention relates to a valve for an aerosol container with the aid of which a quantity of the contents thereof can be dispensed.
  • the invention has particular application to the dispensing of metered doses of medicaments, though it is applicable to the dispensing of aerosols generally.
  • Containers for aerosol formulations commonly comprise a vial body coupled to a valve.
  • the valve comprises a valve stem through which the formulation is dispensed.
  • the valve includes a rubber valve seal intended to allow reciprocal movement of the valve stem while preventing leakage of propellant from the container.
  • valve stem tends to stick, pause, or drag during the actuation cycle with the result that the valve stem may not move smoothly, particularly when released. This may be partly caused by the drug sedimenting or precipitating out of the drug-propellant suspension or solution formulation and depositing on the internal valve components, the presence of drug on the sliding interface creating increased friction during operation.
  • Prior art seals generally comprise a rubber ring formed by stamping out a ring shape from a sheet of rubber material.
  • the ring aperture thus, inevitably has square-cut edges which present a relatively high area of contact between the seal and the stem. Furthermore, when the valve stem is moved in such square-cut seals the seal deforms in such a way that the surface area, and hence the frictional contact area, between the seal and stem increases.
  • valve seal is shaped such as to reduce the area of contact between the seal and the stem.
  • a ring may be formed having a ring aperture with rounded edges.
  • the area of contact between the seal and the stem is less than that for a ring of equivalent thickness having square-cut edges.
  • the seal On movement of the stem within the seal there is also less tendency for the seal to deform such as to increase the contact area between the seal and the stem.
  • WO-A-99/00315 discloses a value having the pre-characterising clause of claim 1.
  • EP-A-0870699 discloses various other valves.
  • the area of contact between the sealing ring(s) and the valve stem is less than 90%, more preferably less than 70%, most preferably less than 50% of what the area of contact would be if the inner surface of the sealing ring(s) had square-cut edges.
  • the inner surface the first and/or second sealing ring presents a lobed surface to the stem. That is to say the surface comprises one or more lobe features.
  • all the stem-receiving edges of the inner surface of the first and/or second sealing rings are rounded.
  • first sealing ring and/or second sealing ring comprises an elastomeric material.
  • the ring is typically resiliently deformable.
  • the elastomeric material may either comprise a thermoplastic elastomer (TPE) or a thermoset elastomer which may optionally be cross-linked.
  • the sealing ring may also comprise a thermoplastic elastomer blend or alloy in which an elastomeric material is dispersed in a thermoplastic matrix.
  • the elastomers may optionally additionally contain conventional polymer additives such as processing aids, colorants, tackifiers, lubricants, silica, talc, or processing oils such as mineral oil in suitable amounts.
  • thermoset rubbers include butyl rubbers, chloro-butyl rubbers, bromobutyl rubbers, nitrile rubbers, silicone rubbers, flurosilicone rubbers, fluorocarbon rubbers, polysulphide rubbers, polypropylene oxide rubbers, isoprene rubbers, isoprene-isobutene rubbers, isobutylene rubbers or neoprene (polychloroprene) rubbers.
  • Suitable thermoplastic elastomers comprise a copolymer of about 80 to about 95 mole percent ethylene and a total of about 5 to about 20 mole percent of one or more comonomers selected from the group consisting of 1-butene, 1-hexene, and 1-octene as known in the art. Two or more such copolymers may be blended together to form a thermoplastic polymer blend.
  • thermoplastic elastomers are the styrene-ethylene/butylene-styrene block copolymers. These copolymers may additionally comprise a polyolefin (e.g. polypropylene) and a siloxane.
  • a polyolefin e.g. polypropylene
  • siloxane e.g. siloxane
  • Thermoplastic elastomeric material may also be selected from one or more of the following: polyester rubbers, polyurethane rubbers, ethylene vinyl acetate rubber, styrene butadiene rubber, copolyether ester TPE, olefinic TPE, polyester amide TPE and polyether amide TPE.
  • elastomers include ethylene propylene diene rubber (EPDM).
  • EPDM ethylene propylene diene rubber
  • the EPDM may be present on its own or present as part of a thermoplastic elastomer blend or alloy, e.g. in the form of particles substantially uniformly dispersed in a continuous thermoplastic matrix (e.g. polypropylene or polyethylene).
  • a continuous thermoplastic matrix e.g. polypropylene or polyethylene
  • Commercially available thermoplastic elastomer blend and alloys include the SANTOPRENETM elastomers.
  • Other suitable thermoplastic elastomer blends include butyl-polyethylene (e.g. in a ratio ranging between about 2:3 and about 3:2) and butyl-polypropylene.
  • elastomeric materials can be prepared using methods known to those skilled in the art.
  • the first sealing ring and/or the second sealing ring additionally comprises lubricant material.
  • the first sealing ring and/or the second sealing ring comprises up to 30%, preferably from 5 to 20% lubricant material.
  • the stem comprises lubricant material.
  • the valve stem comprises up to 30%, preferably from 5 to 20% lubricant material.
  • 'lubricant herein means any material which reduces friction between the valve stem and seal.
  • Suitable lubricants include silicone oil or a fluorocarbon polymer such as polytetrafluoroethane (PTFE) or fluoroethylene propylene (FEP).
  • PTFE polytetrafluoroethane
  • FEP fluoroethylene propylene
  • Lubricant can be applied to the stem, first sealing ring or second sealing ring by any suitable process including coating and impregnation, such as by injection or a tamponage process.
  • an aerosol container comprising a valve as described hereinabove.
  • the aerosol container comprises a suspension of a medicament in a propellant.
  • the propellant is liquefied HFA134a or HFA-227 or mixtures thereof.
  • the medicament is selected from albuterol, salmeterol, fluticasone propionate, beclomethasone dipropionate and ipratropium bromide and salts or solvates thereof and any combination thereof.
  • a valve according to the invention is shown in Figure 1 and comprises a valve body 1 sealed in a ferrule 2 by means of crimping, the ferrule itself being set on the neck of a container (not shown) with interposition of a gasket 3 in a well-known manner.
  • the container is loadable with a suspension of medicament, such as salmeterol xinafoate in liquid propellant HFA134a.
  • the valve body 1 is formed at its lower part with a metering chamber 4, and its upper part with a sampling chamber 5 which also acts as a housing for a return spring 6.
  • the words "upper” and “lower” are used for the container when it is in a use orientation with the neck of the container and valve at the lower end of the container which corresponds to the orientation of the valve as shown in Figure 1.
  • a valve stem 7 Inside the valve body 1 is disposed a valve stem 7, a part 8 of which extends outside the valve through lower stem seal 9 and ferrule 2.
  • the stem part 8 is formed with an inner axial or longitudinal canal 10 opening at the outer end of the stem and in communication with a radial passage 11.
  • the upper portion of stem 7 has a diameter such that it can pass slidably through an opening in an upper stem seal 12 and will engage the periphery of that opening sufficiently to provide a seal.
  • the stem seals 9 and 12 are made by a moulding process and have rounded points of contact with the valve stem 7.
  • Upper stem seal 12 is held in position against a step 13 formed in the valve body 1 between the said lower and upper parts by a sleeve 14 which defines the metering chamber 4 between lower stem seal 9 and upper stem seal 12.
  • the valve stem 7 has a passage 15 which, when the stem is in the inoperative position shown, provides a communication between the metering chamber 4 and sampling chamber 5, which itself communicates with the interior of the container via orifice 16 formed in the side of the valve body 1.
  • Valve stem 7 is biased downwardly to the inoperative position by return spring 6 and is provided with a shoulder 17 which abuts against lower stem seal 9. In the inoperative position as shown in Figure 1 shoulder 17 abuts against lower stem seal 9 and radial passage 11 opens below lower stem seal 9 so that the metering chamber 4 is isolated from canal 10 and suspension inside cannot escape.
  • a ring 18 having a "U" shaped cross section extending in a radial direction is disposed around the valve body below orifice 16 so as to form a trough 19 around the valve body.
  • the ring is formed as a separate component having an inner annular contacting rim of a diameter suitable to provide a friction fit over the upper part of valve body 1, the ring seating against step 13 below the orifice 16.
  • the ring 18 may alternatively be formed as an integrally moulded part of valve body 1.
  • the container is first shaken to homogenise the suspension within the container.
  • the user then depresses the valve stem 7 against the force of the spring 6.
  • both ends of the passage 15 come to lie on the side of upper stem seal 12 remote from the metering chamber 4.
  • a dose is metered within the metering chamber.
  • Continued depression of the valve stem will move the radial passage 11 into the metering chamber 4 while the upper stem seal 12 seals against the valve stem body.
  • the metered dose can exit through the radial passage 11 and the outlet canal 10.
  • Figure 2 shows a cut-away detail of a seal-stem contact point of a valve herein.
  • the upright valve stem 108 which has a circular cross-section is sealingly contacted by a sealing ring 112.
  • the ring aperture 130 of the sealing ring 112 has rounded edges. It may be understood that the area of contact of the ring 112 with the stem 108 is less than it would be if the ring 112 had square-cut edges.
  • the stem 108 is moved upwards, the ring 112 will tend to flex into free-space 140.
  • Figure 3 shows a cut-away detail of a seal-stem contact point of a second valve herein.
  • the upright valve stem 208 which has a circular cross-section is sealingly contacted by a sealing ring 212.
  • the ring aperture of the sealing ring 212 is edged by two rounded lobes 230, 232.
  • the area of contact of the ring 212 with the stem 208 is less than it would be if the ring 212 had square-cut edges.
  • the well 242 may be wholly or partially filled with a lubricant material.
  • Figures 4a and 4b show a cut-away detail of a seal-stem contact point of a prior art valve, wherein Figure 4a shows a rest configuration and Figure 4b shows the configuration when the valve is in an active position.
  • the upright valve stem 308 which has a circular cross-section is sealingly contacted by a sealing ring 312.
  • the ring aperture 330 of the sealing ring 312 has square-cut edges 330.
  • sealing ring a number of different configurations of the sealing ring are possible, in addition to those described in Figures 2 and 3, in which the contact area between the sealing ring and the valve stem is reduced.
  • One possible configuration is similar to that shown in Figure 3 but the ring aperture is edged by more than 2 lobes.
  • Another possible configuration has a sealing ring aperture with straight tapered edges leading to a point (such that its cross section is triangular in shape) which has reduced contact with the valve stem compared to straight cut edges.
  • a lobed version of this sealing ring is also possible wherein there are two or more lobes each tapered to a point.
  • a further configuration which reduces the contact area with the valve stem has sections of the top and bottom sides of the ring aperture cut away to leave a smaller projecting portion to form a seal with the valve stem.
  • the projecting portion may have straight cut or shaped edges. Cutting one or more grooves or small channels in the non stem-receiving surfaces of the sealing ring provides space for the stem-receiving part of the sealing ring to move into upon movement of the valve stem, resulting in reduced deformation and friction at the contact surface with the valve stem.
  • any of the parts of the metering valve which contact the medicament suspension may be coated with materials such as fluoropolymer materials which reduce the tendency of medicament to adhere thereto.
  • Suitable fluoropolymers include polytetrafluoroethylene (PTFE) and fluoroethylene propylene (FEP).
  • PTFE polytetrafluoroethylene
  • FEP fluoroethylene propylene
  • Any movable parts may also have coatings applied thereto which enhance their desired movement characteristics. Frictional coatings may therefore be applied to enhance frictional contact and lubricants used to reduce frictional contact as necessary.
  • the aerosol container and valve of the invention is suitable for dispensing medicament, particularly for the treatment of respiratory disorders such as asthma and chronic obstructive pulmonary disease (COPD).
  • respiratory disorders such as asthma and chronic obstructive pulmonary disease (COPD).
  • COPD chronic obstructive pulmonary disease
  • Appropriate medicaments may thus be selected from, for example, analgesics, e.g., codeine, dihydromorphine, ergotamine, fentanyl or morphine; anginal preparations, e.g., diltiazem; antiallergics, e.g., cromoglycate, ketotifen or nedocromil; antiinfectives e.g., cephalosporins, penicillins, streptomycin, sulphonamides, tetracyclines and pentamidine; antihistamines, e.g., methapyrilene; anti- inflammatories, e.g., beclomethasone dipropionate, fluticasone propionate, flunisolide, budesonide, rofleponide, mometasone furoate or triamcinolone acetonide; antitussives, e.g., noscapine; bron
  • the medicaments may be used in the form of salts, (e.g., as alkali metal or amine salts or as acid addition salts) or as esters (e.g., lower alkyl esters) or as solvates (e.g., hydrates) to optimise the activity and/or stability of the medicament.
  • salts e.g., as alkali metal or amine salts or as acid addition salts
  • esters e.g., lower alkyl esters
  • solvates e.g., hydrates
  • Preferred medicaments are selected from albuterol, salmeterol, fluticasone propionate and beclomethasone dipropionate, and ipratropium bromide and salts or solvates thereof, e.g., the sulphate of albuterol and the xinafoate of salmeterol.
  • Medicaments can also be delivered in combinations.
  • Preferred formulations containing combinations of active ingredients contain salbutamol (e.g., as the free base or the sulphate salt) or salmeterol (e.g., as the xinafoate salt) in combination with an anti-inflammatory steroid such as a beclomethasone ester (e.g., the dipropionate) or a fluticasone ester (e.g., the propionate).
  • an anti-inflammatory steroid such as a beclomethasone ester (e.g., the dipropionate) or a fluticasone ester (e.g., the propionate).

Landscapes

  • Chemical & Material Sciences (AREA)
  • Dispersion Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Mechanical Engineering (AREA)
  • Containers And Packaging Bodies Having A Special Means To Remove Contents (AREA)
  • Magnetically Actuated Valves (AREA)
  • Electrically Driven Valve-Operating Means (AREA)
  • Temperature-Responsive Valves (AREA)
  • Nozzles (AREA)
  • Fluid-Driven Valves (AREA)
  • Compressor (AREA)

Claims (15)

  1. Ventil für einen Aerosolbehälter, mit:
    einem Ventilkörper (1) mit einer Abmesskammer (4) mit einer ersten und einer zweiten Öffnung, und einer Probenkammer (5) angrenzend an die zweite Öffnung; wobei sich innerhalb des Ventilkörpers ein erster Dichtungsring (9) bei der ersten Öffnung und ein zweiter Dichtungsring (12) bei der zweiten Öffnung zwischen der Abmesskammer (4) und der Probenkammer (5) befindet; und
    einem Ventilschaft (7), der sich durch die Abmesskammer hindurch über die erste und die zweite Öffnung hinweg erstreckt und für eine gleitende Bewegung innerhalb der Abmesskammer des Ventils angebracht ist, wobei eine äußere Oberfläche des Ventilschafts in gleitendem abdichtendem Kontakt mit einer inneren Oberfläche (130; 230) sowohl des ersten als auch des zweiten Dichtungsrings steht, wobei der Ventilschaft einen Ausgabedurchgang (10) und einen Transferdurchgang (15) hat und gleitend und abdichtend innerhalb des ersten und des zweiten Dichtungsrings aus einer geschlossenen Ventilstellung, in welcher der Ausgabekanal von der Abmesskammer isoliert ist und die Abmesskammer über den Transferdurchgang in Verbindung mit der Probenkammer steht, in eine offene Ventilstellung beweglich ist, in welcher der Ausgabedurchgang in Verbindung mit der Abmesskammer steht und der Transferdurchgang von der Abmesskammer isoliert ist,
       dadurch gekennzeichnet, dass die inneren Oberflächen des ersten und des zweiten Dichtungsrings jeweils zumindest eine abgerundete Kante in gleitendem abdichtendem Kontakt mit der äußeren Oberfläche des Ventilschafts haben, um so den Kontaktflächenbereich zwischen dem ersten und dem zweiten Dichtungsring und dem Ventilschaft zu reduzieren.
  2. Ventil nach Anspruch 1, bei welchem der erste und/oder der zweite Dichtungsring mittels eines Gießvorgangs ausgebildet ist.
  3. Ventil nach Anspruch 2, bei welchem der Gießvorgang ein Spritzgießvorgang ist.
  4. Ventil nach Anspruch 2, bei welchem der Gießvorgang ein Kompressions-Gießvorgang ist.
  5. Ventil nach Anspruch 2, bei welchem der Gießvorgang ein Transfer-Gießvorgang ist.
  6. Ventil nach einem der Ansprüche 1 bis 5, bei welchem die innere Oberfläche des ersten und/oder des zweiten Dichtungsrings eine hin zu der äußeren Oberfläche des Schafts gewölbte Oberfläche aufweist.
  7. Ventil nach Anspruch 6, bei welchem die gewölbte Oberfläche und die äußere Oberfläche des Schafts zumindest einen Schacht (242) definieren.
  8. Ventil nach Anspruch 7, bei welchem der zumindest eine Schacht ein Schmiermaterial beinhaltet.
  9. Ventil nach einem der Ansprüche 1 bis 8, bei welchem der erste und/oder der zweite Dichtungsring ein elastomerisches Material aufweist.
  10. Ventil nach Anspruch 9, bei welchem das elastomerische Material aus der Gruppe ausgewählt ist, die besteht aus
    (a) einem thermoplastischen Elastomer, das ein Copolymer von ungefähr 80 bis ungefähr 95 Molprozent Ethylen und insgesamt ungefähr 5 bis ungefähr 20 Molprozent aus 1-Buten, 1-Hexen und/oder 1-Octen aufweist,
    (b) einem Styren-Ehtylen/Butylen-Styrenblockcopolymer,
    (c) einem Ethylenpropylendiengummi (EPDM),
    (d) einer thermoplastischen Elastomermischung von EPDM, dispergiert in einer Polypropylen- oder Polyethylen-Marix,
    (e) einem Butylpolyethylen,
    (f) einem Butyl-Polypropylen
       und allen Mischungen daraus.
  11. Ventil nach einem der Ansprüche 1 bis 10, bei welchem der erste und/oder der zweite Dichtungsring außerdem ein Schmiermaterial aufweist.
  12. Aerosolbehälter mit einem Ventil nach einem der Ansprüche 1 bis 11.
  13. Aerosolbehälter nach Anspruch 12, mit einer Suspension eines Medikaments in einem Treibmittel.
  14. Aerosolbehälter nach Anspruch 13, bei welchem das Treibmittel verflüssigtes HFA134a oder HFA-227 oder Mischungen daraus ist.
  15. Aerosolbehälter nach Anspruch 13 oder 14, bei welchem das Medikament ausgewählt ist aus der Gruppe, die aus Albuterol, Salmeterol, Fluticasonpropionat, Beclomethasondipropionat, Ipratropiumbromid und Salzen oder Solvaten von diesen und allen Kombinationen daraus besteht.
EP00915150A 1999-03-24 2000-02-23 Ventil Expired - Lifetime EP1144272B1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9906640.9A GB9906640D0 (en) 1999-03-24 1999-03-24 Valve
GB9906640 1999-03-24
PCT/EP2000/001444 WO2000056632A2 (en) 1999-03-24 2000-02-23 Valve

Publications (2)

Publication Number Publication Date
EP1144272A2 EP1144272A2 (de) 2001-10-17
EP1144272B1 true EP1144272B1 (de) 2005-08-17

Family

ID=10850171

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00915150A Expired - Lifetime EP1144272B1 (de) 1999-03-24 2000-02-23 Ventil

Country Status (13)

Country Link
EP (1) EP1144272B1 (de)
JP (1) JP2002540017A (de)
CN (1) CN1344217A (de)
AT (1) ATE302151T1 (de)
AU (1) AU3656200A (de)
BR (1) BR0009227A (de)
CA (1) CA2366958A1 (de)
DE (1) DE60022007T2 (de)
GB (1) GB9906640D0 (de)
HK (1) HK1039602A1 (de)
MX (1) MXPA01009570A (de)
WO (1) WO2000056632A2 (de)
ZA (1) ZA200106110B (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9918627D0 (en) 1999-08-07 1999-10-13 Glaxo Group Ltd Valve
CA2431910A1 (en) * 2000-12-22 2002-07-04 Glaxo Group Limited Metered dose inhaler for salmeterol xinafoate
JP2005515132A (ja) 2001-12-31 2005-05-26 スリーエム イノベイティブ プロパティズ カンパニー 計量弁に用いる弁ステム
GB2385315B (en) * 2002-01-15 2004-06-30 Bespak Plc Improvements in or relating to valves for dispensers
GB0302812D0 (en) * 2003-02-07 2003-03-12 Wickham Mark D Metering valves for dispensers
GB2417479B (en) * 2004-08-26 2006-09-13 Bespak Plc Improvements in metering valves for pressurised dispensing containers
US9010589B2 (en) * 2008-10-22 2015-04-21 Scholle Corporation Self sealing bag in box cap assembly
GB201110058D0 (en) * 2011-06-15 2011-07-27 3M Innovative Properties Co Medicinal inhalation devices, valves and components thereof
JP2020006307A (ja) * 2018-07-06 2020-01-16 三浦工業株式会社 洗浄器
FR3085734B1 (fr) * 2018-09-11 2021-01-01 Aptar France Sas Joint de valve et valve doseuse pour distributeur de produit fluide.
CN109519579A (zh) * 2018-12-26 2019-03-26 万通(苏州)定量阀系统有限公司 阀门

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1437899A (fr) * 1965-06-18 1966-05-06 Angus George Co Ltd Joint d'étanchéité
DE4123392A1 (de) * 1991-07-15 1993-01-21 Wolf Woco & Co Franz J Wellendichtring
EP0870699A3 (de) * 1995-03-10 1998-10-21 Minnesota Mining And Manufacturing Company Ventil für Aerosolbehälter
GB2329939A (en) * 1997-06-26 1999-04-07 Glaxo Group Ltd Self-lubricating valve stem for aerosol containers

Also Published As

Publication number Publication date
ZA200106110B (en) 2002-07-25
DE60022007D1 (de) 2005-09-22
BR0009227A (pt) 2001-12-26
CA2366958A1 (en) 2000-09-28
HK1039602A1 (zh) 2002-05-03
MXPA01009570A (es) 2002-05-14
GB9906640D0 (en) 1999-05-19
JP2002540017A (ja) 2002-11-26
WO2000056632A2 (en) 2000-09-28
DE60022007T2 (de) 2006-05-04
AU3656200A (en) 2000-10-09
WO2000056632A3 (en) 2000-12-21
EP1144272A2 (de) 2001-10-17
CN1344217A (zh) 2002-04-10
ATE302151T1 (de) 2005-09-15

Similar Documents

Publication Publication Date Title
US7383970B2 (en) Valve with a two-component seal
EP1200321B1 (de) Ventil mit einem ventilschaftwischer
EP0991578B1 (de) Aerosolbehälter für arzneimittel
AU744384B2 (en) Valve for aerosol container
EP1144272B1 (de) Ventil
EP1324796A1 (de) Medikamentenspender
US20040129737A1 (en) Valves for use in containers having valve stems slidably movable within round-edged sealing rings
US20040223916A1 (en) Canister for a metered dose inhaler
MXPA99011752A (en) Valve for aerosol container
MXPA99011989A (en) Valve for aerosol container

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20010716

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

XX Miscellaneous (additional remarks)

Free format text: DERZEIT SIND DIE WIPO-PUBLIKATIONSDATEN A3 NICHT VERFUEGBAR.

17Q First examination report despatched

Effective date: 20031119

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRE;WARNING: LAPSES OF ITALIAN PATENTS WITH EFFECTIVE DATE BEFORE 2007 MAY HAVE OCCURRED AT ANY TIME BEFORE 2007. THE CORRECT EFFECTIVE DATE MAY BE DIFFERENT FROM THE ONE RECORDED.SCRIBED TIME-LIMIT

Effective date: 20050817

Ref country code: CH

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20050817

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20050817

Ref country code: BE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20050817

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20050817

Ref country code: LI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20050817

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20050817

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

XX Miscellaneous (additional remarks)

Free format text: DERZEIT SIND DIE WIPO-PUBLIKATIONSDATEN A3 NICHT VERFUEGBAR.

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REF Corresponds to:

Ref document number: 60022007

Country of ref document: DE

Date of ref document: 20050922

Kind code of ref document: P

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20051117

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20051117

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20051117

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20051128

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20060117

NLV1 Nl: lapsed or annulled due to failure to fulfill the requirements of art. 29p and 29m of the patents act
PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20060223

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20060228

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20060228

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

ET Fr: translation filed
PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20060518

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1039602

Country of ref document: HK

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20050817

REG Reference to a national code

Ref country code: FR

Ref legal event code: CA

Effective date: 20131004

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 16

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 17

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 18

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 19

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20190115

Year of fee payment: 20

Ref country code: FR

Payment date: 20190117

Year of fee payment: 20

Ref country code: GB

Payment date: 20190128

Year of fee payment: 20

REG Reference to a national code

Ref country code: DE

Ref legal event code: R071

Ref document number: 60022007

Country of ref document: DE

REG Reference to a national code

Ref country code: GB

Ref legal event code: PE20

Expiry date: 20200222

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20200222